Cipla Limited has informed the Exchange about Investor Presentation
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cipla shared its Q4FY25 and FY25 investor presentation on 13th May 2025, reporting strong financial performance. Q4FY25 revenue grew 9% YoY to INR 6,730 Cr, with EBITDA up 17% to INR 1,538 Cr and PAT rising 30% to INR 1,222 Cr. For the full year FY25, revenue stood at INR 27,548 Cr (up 8%), EBITDA at INR 7,128 Cr (up 14%), and PAT at INR 5,273 Cr (up 28%), with EBITDA margin expanding 139 bps to 25.9% and PAT margin improving 301 bps to 19.1%. North America revenue grew 16% to $934 Mn, One India delivered 7% growth to INR 11,615 Cr, and the company holds a $1 Bn+ net cash position. Key highlights include Foracort crossing the INR 900 Cr mark (a first in IPM history), 5 USFDA inspections all classified as VAI, and 175 approved ANDAs/NDAs in the portfolio.
Positive for shareholders — broad-based revenue growth, healthy margin expansion, robust cash balance, and strong ROIC of 33% signal healthy business momentum and capacity for future growth investments.